CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2 enrolled
Drug / intervention
Irreversible Electroporation Ablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02461550
NCT02461550N/ACompleted

Irreversible Electroporation Ablation for Colorectal Metastases to the Lung

Memorial Sloan Kettering Cancer Center·interventional·Posted Jun 3, 2015·Updated Jan 8, 2018

In Brief

A clinical study evaluating Irreversible Electroporation Ablation for Colorectal Metastases to the Lung. Completed, enrolled 2 participants across 4 sites.

Detailed Summary

The investigators are investigating the use of a new cancer treatment called Irreversible Electroporation (IRE). This treatment delivers electrical energy between two needles placed in a cancer. The electrical energy causes cells to die. While this has been used in patients for different applications, the investigators are trying to understand how safe and well it works in colon cancer that has spread to the lung. Once the irreversible electroporation procedure is completed during the operation, the surgeon will then remove the cancer according to standard procedure. As part of the study, they will be measuring safety of the electrical energy delivered and will be reviewing the resected specimen under the microscope.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 3, 2015
Enrollment StartMay 1, 2015
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.1 years ago

Interventions

Irreversible Electroporation Ablationdevice